Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)

Vittorio Pengo; Luciano Crippa; Anna Falanga; Guido Finazzi; Francesco Marongiu; Gualtiero Palareti; Daniela Poli; Sophie Testa; Eros Tiraferri; Alberto Tosetto; Armando Tripodi; Cesare Manotti

doi:10.1160/TH11-05-0358

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)

Vittorio Pengo, Luciano Crippa, Anna Falanga, Guido Finazzi, Francesco Marongiu, Gualtiero Palareti, Daniela Poli, Sophie Testa, Eros Tiraferri, Alberto Tosetto, Armando Tripodi, Cesare Manotti

Fondazione IRCCS Ca' Granda- Ospedale Maggiore Policlinico

Research output: Contribution to journal › Article › peer-review

Abstract

Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.

Original language	English
Pages (from-to)	868-876
Number of pages	9
Journal	Thrombosis and Haemostasis
Volume	106
Issue number	5
DOIs	https://doi.org/10.1160/TH11-05-0358
Publication status	Published - Nov 2011

Keywords

Clinical trials
Heart
Oral anticoagulants
Prevention

ASJC Scopus subject areas

Hematology

Access to Document

10.1160/TH11-05-0358

Fingerprint

Dive into the research topics of 'Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)'. Together they form a unique fingerprint.

Cite this

Pengo, V., Crippa, L., Falanga, A., Finazzi, G., Marongiu, F., Palareti, G., Poli, D., Testa, S., Tiraferri, E., Tosetto, A., Tripodi, A., & Manotti, C. (2011). Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA). Thrombosis and Haemostasis, 106(5), 868-876. https://doi.org/10.1160/TH11-05-0358

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA). / Pengo, Vittorio; Crippa, Luciano; Falanga, Anna; Finazzi, Guido; Marongiu, Francesco; Palareti, Gualtiero; Poli, Daniela; Testa, Sophie; Tiraferri, Eros; Tosetto, Alberto; Tripodi, Armando; Manotti, Cesare.

In: Thrombosis and Haemostasis, Vol. 106, No. 5, 11.2011, p. 868-876.

Research output: Contribution to journal › Article › peer-review

Pengo, V, Crippa, L, Falanga, A, Finazzi, G, Marongiu, F, Palareti, G, Poli, D, Testa, S, Tiraferri, E, Tosetto, A, Tripodi, A & Manotti, C 2011, 'Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)', Thrombosis and Haemostasis, vol. 106, no. 5, pp. 868-876. https://doi.org/10.1160/TH11-05-0358

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G et al. Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA). Thrombosis and Haemostasis. 2011 Nov;106(5):868-876. https://doi.org/10.1160/TH11-05-0358

Pengo, Vittorio ; Crippa, Luciano ; Falanga, Anna ; Finazzi, Guido ; Marongiu, Francesco ; Palareti, Gualtiero ; Poli, Daniela ; Testa, Sophie ; Tiraferri, Eros ; Tosetto, Alberto ; Tripodi, Armando ; Manotti, Cesare. / Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA). In: Thrombosis and Haemostasis. 2011 ; Vol. 106, No. 5. pp. 868-876.

@article{7d5ccb01ee684b579638f77975c310aa,

title = "Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)",

abstract = "Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.",

keywords = "Clinical trials, Heart, Oral anticoagulants, Prevention",

author = "Vittorio Pengo and Luciano Crippa and Anna Falanga and Guido Finazzi and Francesco Marongiu and Gualtiero Palareti and Daniela Poli and Sophie Testa and Eros Tiraferri and Alberto Tosetto and Armando Tripodi and Cesare Manotti",

year = "2011",

month = nov,

doi = "10.1160/TH11-05-0358",

language = "English",

volume = "106",

pages = "868--876",

journal = "Thrombosis and Haemostasis",

issn = "0340-6245",

publisher = "Schattauer GmbH",

number = "5",

}

TY - JOUR

T1 - Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)

AU - Pengo, Vittorio

AU - Crippa, Luciano

AU - Falanga, Anna

AU - Finazzi, Guido

AU - Marongiu, Francesco

AU - Palareti, Gualtiero

AU - Poli, Daniela

AU - Testa, Sophie

AU - Tiraferri, Eros

AU - Tosetto, Alberto

AU - Tripodi, Armando

AU - Manotti, Cesare

PY - 2011/11

Y1 - 2011/11

N2 - Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.

AB - Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with.

KW - Clinical trials

KW - Heart

KW - Oral anticoagulants

KW - Prevention

UR - http://www.scopus.com/inward/record.url?scp=80155206426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155206426&partnerID=8YFLogxK

U2 - 10.1160/TH11-05-0358

DO - 10.1160/TH11-05-0358

M3 - Article

C2 - 21946939

AN - SCOPUS:80155206426

VL - 106

SP - 868

EP - 876

JO - Thrombosis and Haemostasis

JF - Thrombosis and Haemostasis

SN - 0340-6245

IS - 5

ER -

Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this